This analysis examines the historical and forecast performance for Boehringer Ingelheim in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
* Gain insight into Boehringer Ingelheim's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Boehringer Ingelheim over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
* Benchmark Boehringer Ingelheim's performance against key rivals in the prescription pharmaceutical sector* Boehringer Ingelheim has achieved impressive historical revenue growth, but without in-licensing deals or acquisitions, its performance is set to wane* Recently launched Pradaxa is expected to reach blockbuster status. Will this and other launches be sufficient to offset major patent expiries?
------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/
------------------------------------------------------------
Report Table of Contents:
Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-
Financial performance, 2003-
Boehringer Ingelheim: PharmaVitae forecasts at a glance
Strategic insight
New launches struggle to match the decline of existing products
External product deals needed to extend growth
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest prescription pharma product news
Q3
Latest corporate news
Q4
COMPANY INTRODUCTION
Key findings
Background
M&A history
Current corporate structure
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-
Product analysis
Product analysis, 2003-
Product analysis, 2009-
Therapy area analysis
Geographic analysis
Launch/core/
Explanation of launch/core/
Launch analysis, 2009-
Core analysis, 2009-
Expiry analysis, 2009-
Generics analysis, 2009-
Launch/core/
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-
Operating costs and profit analysis
Operating costs and profit analysis, 2002-
Operating cost ratio and profit margin analysis, 2003-
Operating cost ratio and profit margin analysis, 2009-
APPENDIX
R&D pipeline
References
Abbreviations
Exchange rates
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
# # #
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
